Core Viewpoint - Phio Pharmaceuticals Corp. has announced the exercise of warrants that will generate approximately $13.4 million in gross proceeds, aimed at advancing its clinical development activities for its lead product, PH-762, targeting skin cancers [1][4]. Group 1: Warrant Exercise Details - The company has entered into agreements to exercise warrants for a total of 5,663,182 shares of common stock, with exercise prices ranging from $2.00 to $5.45 per share [1]. - The exercise includes 60,000 shares at $2.00, 948,596 shares at $2.485, and 4,654,586 shares at a reduced price of $2.05 [1]. - The gross proceeds from these exercises are expected to be around $13.4 million before deducting fees and expenses [1]. Group 2: New Warrants and Offerings - In exchange for the immediate cash exercise of the warrants, holders will receive new unregistered warrants to purchase up to 8,855,248 shares of common stock [3]. - The offering will occur in two closings, with the first expected on or about November 4, 2025, and the second by November 18, 2025 [3]. - The new warrants will have an exercise price of $2.05 per share and will be immediately exercisable for a term of twenty-four months [3]. Group 3: Use of Proceeds - The net proceeds from the warrant exercises will primarily be used for working capital and to accelerate the completion of development activities for PH-762, following positive trial outcomes [4]. Group 4: Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on immuno-oncology therapeutics, utilizing its INTASYL® gene silencing technology [8]. - The lead clinical program, PH-762, targets the PD-1 gene and is currently in a Phase 1b trial for treating various skin cancers [8].

Core Points - Nova Capital Trading Limited has filed an early warning report regarding the acquisition of 9,050,000 common shares of Glow Lifetech Corp through the exercise of warrants [1] - Prior to the acquisition, Nova Capital held 27,036,167 common shares and 25,166,667 warrants, representing approximately 15.77% of the outstanding shares on an undiluted basis and 26.56% on a partially diluted basis [2] - After the acquisition, Nova Capital's holdings increased to 36,086,167 common shares and 16,116,667 warrants, equating to approximately 20.00% of the outstanding shares on an undiluted basis while maintaining 26.56% on a partially diluted basis [2] - The common shares were acquired for investment purposes, with a long-term view, and the acquirer may consider additional acquisitions or sales depending on market conditions [3]

Core Viewpoint - Peraso Inc. has entered into a definitive agreement to exercise Series C warrants, allowing the purchase of 952,380 shares at a reduced price, generating approximately $1.1 million in gross proceeds [1]. Group 1 - The company is a pioneer in mmWave wireless technology solutions [1]. - The Series C warrants were originally issued in November 2024 [1]. - The reduced exercise price for the warrants is set at $1.18 per share [1]. Group 2 - The gross proceeds expected from this transaction are approximately $1.1 million before deducting fees and expenses [1].

Core Viewpoint - Moleculin Biotech, Inc. has announced agreements for the immediate exercise of existing warrants, which will generate approximately $6.0 million in gross proceeds for the company [1][3]. Group 1: Financial Transactions - The company has entered into agreements for the immediate exercise of warrants to purchase up to 16,216,216 shares of common stock at an exercise price of $0.37 per share [1]. - Roth Capital Partners is acting as the financial advisor for this transaction [2]. - In exchange for the immediate exercise of the warrants, the company will issue new unregistered warrants for up to 64,864,864 shares at an exercise price of $0.55 per share, subject to shareholder approval [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for working capital and general corporate purposes [3]. Group 3: Company Overview - Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses [6]. - The lead program, Annamycin, is designed to treat relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases [6][7]. - The company has initiated the MIRACLE trial, evaluating Annamycin in combination with cytarabine for AML treatment [7]. - Additionally, the company is developing WP1066, an immune/transcription modulator targeting various cancers, and WP1122 for potential treatment of pathogenic viruses [8].

Core Viewpoint - Phio Pharmaceuticals Corp. has announced the exercise of warrants that will generate approximately $2.5 million in gross proceeds, aimed at supporting its clinical-stage siRNA biopharmaceutical operations focused on cancer therapeutics [1][4]. Group 1: Warrants and Financial Details - The company entered into agreements to exercise warrants for a total of 928,596 shares of common stock, with exercise prices ranging from $2.00 to $3.00 per share [1]. - The exercise of 100,000 shares will occur at the existing price of $2.00, while 828,596 shares will be exercised at a reduced price of $2.485 per share [1]. - The gross proceeds from this exercise are expected to be around $2.5 million before deducting fees and expenses [1]. Group 2: New Warrants Issuance - In exchange for the immediate cash exercise of the warrants, holders will receive new unregistered warrants for an aggregate of up to 1,857,192 shares at an exercise price of $2.485 per share [3]. - The new warrants will have a term of twenty-four months for 1,538,596 shares and five years for 318,596 shares, effective upon the registration of the shares [3]. Group 3: Use of Proceeds - The company plans to utilize the net proceeds from the offering for working capital and other general corporate purposes [4]. Group 4: Company Overview - Phio Pharmaceuticals is a clinical-stage siRNA biopharmaceutical company that focuses on developing therapeutics using its INTASYL® gene silencing technology, particularly in the field of immuno-oncology [9]. - The lead clinical program, PH-762, targets the PD-1 gene associated with various skin cancers and is currently undergoing a Phase 1b trial [9].

Core Viewpoint - IDEX Biometrics ASA has successfully exercised Warrants B, leading to an increase in share capital and the issuance of new shares at a specified exercise price [2][3]. Group 1: Warrants and Share Capital - A total of 36,767 Warrants B were exercised, resulting in the subscription for 36,767 new shares at an exercise price of NOK 0.15 each [2]. - The Board of Directors has approved the allocation of new shares to the holders of Warrants B, leading to a resolution to increase the company's share capital [2]. - Following the exercise of Warrants B, the company's share capital will amount to NOK 38,316,309.99, divided into 3,831,630,999 shares, each with a nominal value of NOK 0.01 [3]. Group 2: Payment and Registration - Payment for the allocated new shares is due one week after the Board's resolution [3]. - The new shares will be issued upon registration of the share capital increase in the Norwegian Register of Business Enterprises [3]. Group 3: Company Overview - IDEX Biometrics ASA is a global leader in fingerprint biometrics, providing authentication solutions for payments, access control, and digital identity [4]. - The company's biometric solutions are built on patented technologies and target card-based applications for payments and digital authentication [4]. - IDEX partners with leading card manufacturers and technology companies to bring its solutions to market [4].

Company Overview - Vast Resources plc is a UK AIM listed mining company with operations in Romania, Tajikistan, and Zimbabwe [7] - The company focuses on advancing high-quality projects and recommencing production at previously operating mines in Romania [7] Recent Developments - The company announced the exercise of warrants for a total of 195,000,000 new ordinary shares at an exercise price of 0.4 pence per share, raising £780,000 [2] - Application has been made for the new shares to be admitted to trading on the AIM market, with admission expected around 1 May 2025 [3] Share Capital - Following the admission of the new shares, the total issued ordinary share capital will consist of 2,803,607,357 shares, with no shares held in treasury [4] Romanian Operations - Vast holds a 100% interest in Vast Baita Plai SA, which owns the producing Baita Plai Polymetallic Mine, with a total mineral resource of 15,695 tonnes copper equivalent and an exploration target of up to 5.8 million tonnes [8] - The company is also working to bring the Manaila Polymetallic Mine back into production and has received an extended exploitation license for the Manaila Carlibaba area [9][10] Tajikistan Operations - Vast has a joint venture interest in the Takob Mine processing facility, which is fully financed and will provide a 12.25% royalty on sales of non-ferrous concentrate [11] - The company is contracted to develop and manage the Aprelevka gold mines, aiming to increase production from approximately 11,600 ounces of gold and 116,000 ounces of silver per annum to historical peak levels of 27,000 ounces of gold and 250,000 ounces of silver [12]